ArticleTransplantation direct2026
Varying Perfusate Hemoglobin During Normothermic Ex Situ Heart Perfusion: Elevated Hemoglobin Exacerbates Functional Decline Through Hemolysis.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal coronary flow rates for preservation of function during normothermic ex situ heart perfusion.The Journal of thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ex-situ heart perfusion (ESHP) enables improved donor heart preservation, yet still suffers functional decline. The perfusate is 1 area that requires optimization, especially with regard to hemoglobin (Hb) content. We sought to compare performance of concentrated, physiologic, and dilute perfusates in minimally damaged hearts. Methods: Hearts of juvenile Yorkshire pigs (45-55 kg) were procured and subject to 11 h of working-mode ESHP in 1 of 4 groups varying in Hb: concentrated blood (CB, ~12 g/dL Hb, n = 4), whole blood (WB, ~8g/dL Hb, n = 6), plasma (~4g/dL Hb, n = 6, diluted with donor plasma), and control (~4g/dL Hb, n = 5, diluted with modified Krebs-Heinseleit). Functional, metabolic, and hemolytic markers were recorded and compared between groups statistically using appropriate statistical tests. Results: CB hearts exhibited worsened decline from baseline in cardiac index, dP/dT max/min, and stroke work ( Conclusions: Hb dilution appears to lower absolute output but preserves baseline function. Supraphysiologic Hb elevation or sublethal blood cell damage exacerbates hemolysis, which contributes to functional decline during ESHP. Lactate evolution did not appear to associate with the degree of functional loss.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.